期刊文献+

哌立福辛通过激活GSK3β抑制雷帕霉素耐药细胞的生长 被引量:3

Perifosine inhibits growth of rapamycin resistant cells through activating GSK3β
暂未订购
导出
摘要 目的:研究哌立福辛对雷帕霉素耐药的非小细胞肺癌细胞株生长的抑制作用和机制。方法:用SRB法检测哌立福辛单用以及联用LiCl对细胞株生长的抑制作用。用Western blotting法检测哌立福辛对细胞内Akt,GSK3β信号的调控作用。结果:哌立福辛对雷帕霉素敏感和耐药细胞株的生长有相似的抑制作用。在耐药细胞上,哌立福辛未明显抑制Akt的磷酸化,却可以显著抑制GSK3β的磷酸化,从而激活GSK3β。用LiCl抑制GSK3β的活性可以阻断哌立福辛对耐药细胞生长的抑制作用。结论:哌立福辛可以通过激活GSK3β抑制雷帕霉素耐药的非小细胞肺癌细胞的生长。 AIM: To investigate the effects and mechanisms of perifosine on the growth of rapamcyin resistant NSCLC cells. METHODS: The growth inhibitory effects of perfisoine with or without LiCl on NSCLC cells were detected by SRB assay.The regulatory effects of perifosine on Akt,GSK3β singaling were detected by Western blotting.RESULTS:Perifosine had similar inhibitory effects on the growth of rapamycin resistant and sensitive cells.Perifosine inhibited phosphorylation of GSK3β without significant alteration of Akt phosphorylation,and thus activated GSK3β in rapamycin resistant cells.The inhibitor of GSK3β-LiCl blocked perifosine's inhibitory effects on the growth of rapamycin resistant cells.CONCLUSION: Perifosine inhibits growth of rapamycin resistant NSCLC cells through activating GSK3β.
出处 《中国临床药理学与治疗学》 CAS CSCD 2011年第4期389-393,共5页 Chinese Journal of Clinical Pharmacology and Therapeutics
基金 国家自然科学基金(30873099) 教育部科学技术研究重点项目(209050) 南京医科大学引进人才科研启动基金(10RC01)
关键词 耐药性 GSK3Β 雷帕霉素 哌立福辛 Drug resistance GSK3β Rapamycin Perifosine
  • 相关文献

参考文献6

  • 1周星辉,王丙力,谭焕然.大鼠肝实质细胞原代培养模型的研究及其功能鉴定[J].中国临床药理学与治疗学,2005,10(7):743-746. 被引量:9
  • 2Abraham RT, Gibbons JJ. The mammalian target of Rapamycin signaling pathway: twists and turns in the road to cancer therapy[J]. Clin Cancer Res, 2007,13(11): 3109-3114.
  • 3Sun SY, Rosenberg LM, Wang X, et al. Activation of Akt and eIF4E survival pathways by Rapamyeinmediated mammalian target of Rapamycin inhibition [J]. Cancer Res,2005,65(16):7052-7058.
  • 4李婧婧,冯公侃,朱孝峰,张晓实.西妥昔单抗联合顺铂对鼻咽癌荷瘤裸鼠移植瘤生长作用的影响[J].中国临床药理学与治疗学,2008,13(7):735-739. 被引量:5
  • 5Liang J, Slingerland JM. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression [J]. Cell Cycle,2003,2(4): 339-345.
  • 6Fu L, Kim YA, Wang X, et al. Perifosine inhibits mammalian target of Rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy[J]. Cancer Res, 2009,69(23): 8967-8976.

二级参考文献6

  • 1麦海强,曾宗渊,张惠忠,侯景辉,莫浩元,郭翔,闵华庆,洪明晃.内皮素受体A表达与鼻咽癌预后的关系[J].癌症,2005,24(5):611-615. 被引量:5
  • 2Marc I, Brand, Sergio C, David WD, Jeffrey W, Milsom, et al. Development of a reliable colorectal cancer liver metastasis Model[J]. J Surg Res, 1996; 63:425-32
  • 3Ann F, Chambers, Alan C, Groom. Dissemination and growth of cancer cells in metastatic sites [J]. Nature Review Cancer,2002; 2: 563 - 72
  • 4Helene L,Pierre B, Achilles A, Demetriou, Jacek R. Response of cultured fetal and adult rat hepatocytes to growth factors and cyclosporine[J]. Cell Transplantation, 1998; 7: 257 - 66
  • 5黄平.大肠癌肝转移模型研究进展[J].实用肿瘤杂志,1998,13(1):60-63. 被引量:7
  • 6白文启.大肠癌诊治进展中的哲学思考[J].临床医药实践,2003,12(11):875-877. 被引量:1

共引文献12

同被引文献26

  • 1Gills JJ, Dennis PA. Perifosine:update on a novel Akt in- hibitor [ J ]. Cnrr Oncol Rep, 2009, 11 (2) : 102-110.
  • 2Chiarini F, Del Sole M,Mongiorgi S,et al. The novel Akt inhibitor,perifosine,induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in mul- tidrug-resistant human T-acute leukemia cells by a JNK- dependent mechanism [J]. Leukemia, 2008,22 (6) : 1106- 1116.
  • 3David E, Sinha R, Chen J, et al. Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up- regulation of death receptors [J]. Clin Cancer Res, 2008,14(16) : 5090-5098.
  • 4Li Z,Tan F,Liewehr DJ,et al. In vitro and in vivo inhibition of neuroblastoma tumor cell growth by AKT inhibitor peri- fosine[J]. J Nat1 Cancer Inst,2010,102(11):758-770.
  • 5Leighl NB, Dent S, Clemons M,et al. A Phase 2 study of perifosine in advanced or metastatic breast cancer [J]. Breast Cancer Res Treat, 2008,108( 1 ) : 87-92.
  • 6Chee KG, Longmate J, Quinn DI, et al. The AKT inhibitor perifosine in biochemically recurrent prostate cancer:a phase II California/Pittsburgh cancer consortium triM[J]. Clin Genitourin Cancer, 2007,5 (7) : 433-437.
  • 7Cho DC,Hutson TE,Samlowski W,et al. Two phase 2 trials of the novel Akt inhibitor perifosine in patients with ad- vanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy [J]. Cancer, 2012, 118 (24) : 6055 -6062.
  • 8Siegel R, Naishadham D,Jemal A. Cancer statistics, 2012 [J]. CA Cancer J Clin,2012,62( 1 ) : 10-29.
  • 9De Luca A,Maiello MR,D'Alessio A,et al. The RAS/ RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeu- tic approaches [J]. Expert Opin Ther Targets,2012,16 (Suppl 2) :S17-27.
  • 10De Benedetti A, Graft JR. eIF-4E expression and its role in malignancies and metastases [J]. Oncogene,2004,23 (18) :3189-3199.

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部